ZR-75-1 HRAS [ZR-HRAS pool B] cell line
Contributors
| Inventor | Institute |
|---|---|
| Lambert Dorssers | Erasmus University Medical Center (Erasmus MC) |
| SKU: | 154631 |
|---|---|
| Product description: | Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype.Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in human breast cancer cells. This cell line is part of a panel of 16 cell lines (Cat No 154621-154635, 154642) which have been transfected with these genes, plus the parental (Cat No 154547).This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity |
| Alternate name: | HRas Proto-Oncogene, GTPase; Transforming Protein P21 |
| Production details: | Expression constructs with HRAS were transfected into ZR-75-1 cells using FuGENE 6 and selected with G418. After selection for G418 resistance colonies were expanded |
| Parental cell line: | ZR-75-1 |
| Disease: | Cancer |
| Cat. #: | 154631 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Research Fields: | Cancer; Drug development |
| Organism: | Human |
| Tissue: | Breast |
| Model: | Cancer Model |
| Cancer Types In Detail: | Mammary ductal carcinoma |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17?-estradiol |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015. |
|---|
Images
View Gallery
Product Images
161195.jpg
